HRP20202005T1 - Metalne nanočestice, njihova priprava i uporaba - Google Patents
Metalne nanočestice, njihova priprava i uporaba Download PDFInfo
- Publication number
- HRP20202005T1 HRP20202005T1 HRP20202005TT HRP20202005T HRP20202005T1 HR P20202005 T1 HRP20202005 T1 HR P20202005T1 HR P20202005T T HRP20202005T T HR P20202005TT HR P20202005 T HRP20202005 T HR P20202005T HR P20202005 T1 HRP20202005 T1 HR P20202005T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- pharmaceutical composition
- cells
- metal
- group
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 title claims 2
- 210000004027 cell Anatomy 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 6
- 239000002082 metal nanoparticle Substances 0.000 claims 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 239000010931 gold Substances 0.000 claims 4
- 230000005865 ionizing radiation Effects 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 229910052684 Cerium Inorganic materials 0.000 claims 2
- 229910052692 Dysprosium Inorganic materials 0.000 claims 2
- 229910052691 Erbium Inorganic materials 0.000 claims 2
- 229910052693 Europium Inorganic materials 0.000 claims 2
- 229910052689 Holmium Inorganic materials 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 2
- 229910052771 Terbium Inorganic materials 0.000 claims 2
- 229910052775 Thulium Inorganic materials 0.000 claims 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 2
- 229910052769 Ytterbium Inorganic materials 0.000 claims 2
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 2
- 229910052737 gold Inorganic materials 0.000 claims 2
- 229910052735 hafnium Inorganic materials 0.000 claims 2
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims 2
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 229910052715 tantalum Inorganic materials 0.000 claims 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 claims 2
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229910052777 Praseodymium Inorganic materials 0.000 claims 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 claims 1
- 238000010894 electron beam technology Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 229910052746 lanthanum Inorganic materials 0.000 claims 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229910000077 silane Inorganic materials 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (11)
1. Uporaba populacije metalnih nanočestica za pripravu farmaceutskog sastava za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih stanica sisavaca in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje su nanočestice izrađene od metala koji ima atomski broj (Z) od najmanje 25 odabranih između zlata (Au), srebra (Ag), platine (Pt), paladija (Pd), kositara (Sn), tantala (Ta), itterbija (Yb), cirkonija (Zr), hafnija (Hf), terbija (Tb), tulija (Tm), cerija (Ce), disprozija (Dy), erbija (Er), europija (Eu), holmija (Ho), željeza (Fe), lantana (La), neonidija (Nd) i praseodima (Pr), metalna nanočestica u osnovi je sfernog oblika, i srednja najveća veličina metalne jezgre nanočestice populacije je između oko 80 i 105 nm, pri čemu je metalna nanočestica prekrivena biokompatibilnom oblogom.
2. Farmaceutski sastav obuhvaća populaciju metalnih nanočestica za uporabu u metodi narušavanja, izmjene ili uništavanja ciljnih stanica in vivo, odabranih iz grupe koja se sastoji od benignih stanica, premalignih stanica i malignih stanica sisavaca, pri čemu su navedene stanice izložene ionizirajućim zračenjima, gdje su nanočestice izrađene od metala koji imaju atomski broj (Z) od najmanje 25 odabranih između zlata (Au), srebra (Ag), platine (Pt), paladija (Pd), kositara (Sn), tantala (Ta), itterbija (Yb), cirkonija (Zr), hafnija (Hf), terbija (Tb), tulija (Tm), cerija (Ce), disprozija (Dy), erbija (Er), europija (Eu), holmija (Ho), željeza (Fe), lantana (La), neonidija (Nd) i praseodima (Pr), metalna nanočestica u osnovi je sfernog oblika, i srednja najveća veličina metalne jezgre nanočestice populacije je između oko 80 i 105 nm, pri čemu je metalna nanočestica prekrivena biokompatibilnom oblogom.
3. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu je biokompatibilna obloga ne-biorazgradiva obloga odabrana iz grupe koja se sastoji od silicija, aluminija, šećera, fosfata, silana, tiola, cviterionske tvari, lipida, zasićenog polimera ugljika i anorganskog polimera; ili biorazgradiva obloga odabrana iz grupe koja se sastoji od biološkog polimera, fosfolipida, saharida, oligosaharida i polisaharida.
4. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu sastav obuhvaća između otprilike 10-6 nmola i 10-3 nmola metala po ciljnoj stanici.
5. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu metalna nanočestica obuhvaća površinsku komponentu koja omogućuje specifično ciljanje bioloških tkiva ili stanica.
6. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedena ionizirajuća zračenja odabrana iz grupe koja se sastoji od X-zračenja, γ-zračenja, elektronskih zraka i radioizotopnih emisija.
7. Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 6, pri čemu su ionizirajuća zračenja oko 50 KeV do oko 12000 KeV.
8. Uporaba farmaceutskog sastava za uporabu u skladu s patentnim zahtjevom 6, pri čemu su zračenja X-zraka oko 50 KeV do 6000 KeV.
9. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedene maligne stanice stanice iz solidnog tumora.
10. Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu farmaceutski sastav nadalje obuhvaća dodatnu terapijsku tvar namijenjenu za liječenje raka, navedena terapijska tvar je različita od populacije metalnih nanočestica.
11. Uporaba u skladu s bilo kojim od patentnih zahtjeva 1 i 3 do 10 ili farmaceutski sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 2-10, pri čemu navedena stanica sisavca je ljudska stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22457609P | 2009-07-10 | 2009-07-10 | |
| EP09165157A EP2275137A1 (en) | 2009-07-10 | 2009-07-10 | Metallic nanoparticles, preparation and uses thereof |
| EP17152585.0A EP3178494B1 (en) | 2009-07-10 | 2010-07-09 | Metallic nanoparticles, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202005T1 true HRP20202005T1 (hr) | 2021-02-19 |
Family
ID=41110399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170175TT HRP20170175T1 (hr) | 2009-07-10 | 2017-02-02 | Metalne nanočestice, njihova priprava i uporaba |
| HRP20202005TT HRP20202005T1 (hr) | 2009-07-10 | 2020-12-15 | Metalne nanočestice, njihova priprava i uporaba |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170175TT HRP20170175T1 (hr) | 2009-07-10 | 2017-02-02 | Metalne nanočestice, njihova priprava i uporaba |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9700621B2 (hr) |
| EP (3) | EP2275137A1 (hr) |
| JP (1) | JP5739883B2 (hr) |
| KR (1) | KR101670757B1 (hr) |
| CN (1) | CN102470173B (hr) |
| AU (1) | AU2010270225B2 (hr) |
| BR (2) | BR122019025997B8 (hr) |
| CA (1) | CA2765290C (hr) |
| CY (1) | CY1118600T1 (hr) |
| DK (2) | DK3178494T3 (hr) |
| EA (1) | EA020942B1 (hr) |
| ES (2) | ES2616628T3 (hr) |
| HR (2) | HRP20170175T1 (hr) |
| HU (2) | HUE052686T2 (hr) |
| IL (1) | IL217287A (hr) |
| LT (1) | LT2451481T (hr) |
| MA (1) | MA33516B1 (hr) |
| MX (2) | MX347606B (hr) |
| NZ (1) | NZ597564A (hr) |
| PL (2) | PL2451481T3 (hr) |
| PT (2) | PT2451481T (hr) |
| SG (2) | SG177611A1 (hr) |
| SI (1) | SI2451481T1 (hr) |
| WO (1) | WO2011003999A1 (hr) |
| ZA (1) | ZA201200902B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012000311B1 (pt) | 2009-07-08 | 2021-12-21 | Clene Nanomedicine, Inc. | Nanocristais com base em ouro para tratamentos médicos e processos eletroquímicos para a fabricação dos mesmos |
| EP2275137A1 (en) * | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
| US20120190979A1 (en) | 2011-01-24 | 2012-07-26 | Actium BioSystems, LLC | System for automatically amending energy field characteristics in the application of an energy field to a living organism for treatment of invasive agents |
| AU2012300534B2 (en) * | 2011-08-26 | 2016-12-01 | Endomagnetics Ltd | Apparatus for the generation of an energy field for the treatment of cancer in body cavities and parts that are cavity-like |
| WO2013087920A1 (en) | 2011-12-16 | 2013-06-20 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
| UA116007C2 (uk) * | 2013-01-25 | 2018-01-25 | Нанобіотікс | Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку |
| CA2913023C (en) * | 2013-05-30 | 2021-06-08 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| JP6560665B2 (ja) * | 2013-06-20 | 2019-08-14 | ナノビオティックスＮａｎｏｂｉｏｔｉｘ | 医療診断に使用するための組成物および方法 |
| TWI689310B (zh) | 2014-07-11 | 2020-04-01 | 巨生生醫股份有限公司 | 治療鐵缺乏症之方法 |
| JP6778371B2 (ja) * | 2015-01-23 | 2020-11-04 | ミヨシ油脂株式会社 | 金微粒子マトリックスメタロプロテアーゼ阻害剤 |
| AU2016269146B2 (en) | 2015-05-28 | 2021-01-28 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
| DE102017101057A1 (de) * | 2017-01-20 | 2018-07-26 | Fraunhofer-Institut für Angewandte Polymerforschung IAP | Zwitterionische Nanopartikel |
| JP7376901B2 (ja) * | 2017-11-13 | 2023-11-09 | 国立大学法人北海道大学 | 修飾金属ナノ粒子及び医薬組成物 |
| CN110883341B (zh) * | 2018-09-11 | 2021-03-30 | 清华大学 | 金纳米团簇制备方法 |
| JPWO2021060498A1 (hr) * | 2019-09-27 | 2021-04-01 | ||
| KR20230038659A (ko) * | 2020-05-26 | 2023-03-21 | 나노비오띡스 | 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006244A2 (en) * | 1998-07-30 | 2000-02-10 | Hainfeld James F | Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy |
| US20070031337A1 (en) * | 2004-06-22 | 2007-02-08 | Reinhard Schulte | Nanoparticle enhanced proton computed tomography and proton therapy |
| DE102007040934A1 (de) | 2007-08-30 | 2009-03-05 | Man Diesel A/S | Verfahren und Vorrichtung zur Reinigung von Abgas |
| EP2130553A1 (en) * | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| EP2275137A1 (en) * | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
-
2009
- 2009-07-10 EP EP09165157A patent/EP2275137A1/en not_active Withdrawn
-
2010
- 2010-07-09 EP EP10729917.4A patent/EP2451481B1/en active Active
- 2010-07-09 PT PT107299174T patent/PT2451481T/pt unknown
- 2010-07-09 SG SG2012002044A patent/SG177611A1/en unknown
- 2010-07-09 CA CA2765290A patent/CA2765290C/en active Active
- 2010-07-09 HU HUE17152585A patent/HUE052686T2/hu unknown
- 2010-07-09 HU HUE10729917A patent/HUE031796T2/en unknown
- 2010-07-09 PT PT171525850T patent/PT3178494T/pt unknown
- 2010-07-09 MX MX2015010613A patent/MX347606B/es unknown
- 2010-07-09 SG SG10201403832YA patent/SG10201403832YA/en unknown
- 2010-07-09 ES ES10729917.4T patent/ES2616628T3/es active Active
- 2010-07-09 ES ES17152585T patent/ES2837412T3/es active Active
- 2010-07-09 WO PCT/EP2010/059871 patent/WO2011003999A1/en active Application Filing
- 2010-07-09 NZ NZ597564A patent/NZ597564A/xx not_active IP Right Cessation
- 2010-07-09 EA EA201270154A patent/EA020942B1/ru not_active IP Right Cessation
- 2010-07-09 BR BR122019025997A patent/BR122019025997B8/pt not_active IP Right Cessation
- 2010-07-09 JP JP2012519006A patent/JP5739883B2/ja active Active
- 2010-07-09 AU AU2010270225A patent/AU2010270225B2/en not_active Ceased
- 2010-07-09 EP EP17152585.0A patent/EP3178494B1/en active Active
- 2010-07-09 KR KR1020127003701A patent/KR101670757B1/ko active IP Right Grant
- 2010-07-09 US US13/383,049 patent/US9700621B2/en active Active
- 2010-07-09 DK DK17152585.0T patent/DK3178494T3/da active
- 2010-07-09 PL PL10729917T patent/PL2451481T3/pl unknown
- 2010-07-09 SI SI201031410A patent/SI2451481T1/sl unknown
- 2010-07-09 MX MX2012000285A patent/MX2012000285A/es active IP Right Grant
- 2010-07-09 LT LTEP10729917.4T patent/LT2451481T/lt unknown
- 2010-07-09 PL PL17152585T patent/PL3178494T3/pl unknown
- 2010-07-09 CN CN201080031148.1A patent/CN102470173B/zh active Active
- 2010-07-09 DK DK10729917.4T patent/DK2451481T3/en active
- 2010-07-09 BR BR112012000530A patent/BR112012000530B8/pt not_active IP Right Cessation
-
2011
- 2011-12-29 IL IL217287A patent/IL217287A/en active IP Right Grant
-
2012
- 2012-02-07 ZA ZA2012/00902A patent/ZA201200902B/en unknown
- 2012-02-08 MA MA34614A patent/MA33516B1/fr unknown
-
2017
- 2017-02-02 HR HRP20170175TT patent/HRP20170175T1/hr unknown
- 2017-02-07 CY CY20171100166T patent/CY1118600T1/el unknown
- 2017-06-28 US US15/635,252 patent/US10391174B2/en active Active
-
2020
- 2020-12-15 HR HRP20202005TT patent/HRP20202005T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202005T1 (hr) | Metalne nanočestice, njihova priprava i uporaba | |
| Xue et al. | Engineering a biodegradable multifunctional antibacterial bioactive nanosystem for enhancing tumor photothermo-chemotherapy and bone regeneration | |
| Hossain et al. | Nanoparticle location and material-dependent dose enhancement in X-ray radiation therapy | |
| Geng et al. | Thio-glucose bound gold nanoparticles enhance radio-cytotoxic targeting of ovarian cancer | |
| Rashid et al. | Radiosensitization effects and ROS generation by high Z metallic nanoparticles on human colon carcinoma cell (HCT116) irradiated under 150 MeV proton beam | |
| Ma et al. | Shape-dependent radiosensitization effect of gold nanostructures in cancer radiotherapy: comparison of gold nanoparticles, nanospikes, and nanorods | |
| Xiao et al. | On the role of low-energy electrons in the radiosensitization of DNA by gold nanoparticles | |
| Zhang et al. | Enhanced radiation sensitivity in prostate cancer by gold-nanoparticles | |
| HRP20161465T1 (hr) | Anorganske nanočestice visoke gustoće za uništavanje stanica in-vivo | |
| Li et al. | LET-dependent radiosensitization effects of gold nanoparticles for proton irradiation | |
| Carter et al. | Nanoscale energy deposition by X-ray absorbing nanostructures | |
| Ouyang et al. | Potential of using cerium oxide nanoparticles for protecting healthy tissue during accelerated partial breast irradiation (APBI) | |
| Wu et al. | In vitro and in vivo evaluation of multiphase ultrahigh ductility Mg–Li–Zn alloys for cardiovascular stent application | |
| WO2012054471A1 (en) | Monochromatic x-ray devices and methods of use | |
| Torrisi | Gold nanoparticles enhancing protontherapy efficiency | |
| Oliveira et al. | Calcium phosphate-based bioceramics in the treatment of osteosarcoma: Drug delivery composites and magnetic hyperthermia agents | |
| Chen et al. | Albumin-modified gold nanoparticles as novel radiosensitizers for enhancing lung cancer radiotherapy | |
| Anisimova et al. | Anti-tumour activity of Mg-6% Ag and Mg-10% Gd alloys in mice with inoculated melanoma | |
| Cho et al. | Photoperiodic flower mimicking metallic nanoparticles for image-guided medicine applications | |
| Torrisi | Evaluation of the radiotherapy and proton therapy improvements using gold nanoparticles | |
| Ruan et al. | Leveraging Radiation‐triggered Metal Prodrug Activation Through Nanosurface Energy Transfer for Directed Radio‐chemo‐immunotherapy | |
| Dong et al. | Radiotherapy enhancement for human pancreatic carcinoma using a peptide-gold nanoparticle hybrid | |
| Yektamanesh et al. | Characterization of multifunctional β-cyclodextrin-coated Bi2O3 nanoparticles conjugated with curcumin for CT imaging-guided synergetic chemo-radiotherapy in breast cancer | |
| Mohapatra et al. | Stimuli-controlled drug delivery system development with implantable biocompatible chitosan microbeads | |
| Singhal et al. | Metallic Nanoparticles: Applications in Drug Delivery |